Talon Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Talon Therapeutics, Inc. - overview
Established
2002
Location
San Mateo, CA, US
Primary Industry
Biotechnology
About
Talon Therapeutics, Inc. focuses on developing innovative pharmaceutical solutions targeting unmet medical needs, particularly in the areas of oncology and hematology, to improve patient outcomes through advanced therapies. Founded in 2002 in San Mateo, US, Talon Therapeutics, Inc. is engaged in the development of pharmaceutical products.
The company underwent a significant pivot in its business strategy when it was acquired by Spectrum Pharmaceuticals on July 17, 2013, for USD 11. 3 million. Talon Therapeutics has completed a total of 3 deals to date. Talon Therapeutics specializes in advanced pharmaceutical solutions, particularly in oncology and hematology.
Their product offerings focus on innovative therapies aimed at addressing critical medical challenges and improving patient care outcomes. The company distributes its products primarily in North America and Europe, targeting healthcare providers and institutions in these regions. Talon Therapeutics reported zero revenue in the most recent year, 2008. In terms of operational performance, the company recorded an EBITDA of USD -19.
72 mn in 2012, indicating operational challenges during that period. Following its acquisition, Talon Therapeutics aims to leverage recent funding to enhance its product pipeline and market presence. The company is strategizing to expand its product offerings and target new geographic markets. Specific plans include launching new therapies designed to address niche areas within oncology and hematology in the next few years, ensuring alignment with the evolving healthcare landscape.
The resources from the recent acquisition will be utilized to support these development initiatives.
Current Investors
Warburg Pincus, Deerfield Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.talontx.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Talon Therapeutics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2005 | Dec 31, 2006 | Dec 31, 2007 | Dec 31, 2008 | Dec 31, 2009 | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | 1,150,000 | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | (100.0%) | - | - | - | - |
| EBITDA (USD) | (10,163,046) | (45,946,575) | (27,917,013) | (23,664,751) | (18,512,264) | - | - | - |
| Operating Income (USD) | (10,209,006) | (46,054,309) | (28,125,685) | (24,227,352) | (19,600,097) | - | - | - |
| Operating Margin | - | - | (2445.7%) | - | - | - | - | - |
| % EBITDA Margin | - | - | (2427.6%) | - | - | - | - | - |
| NET Income (USD) | (10,042,963) | (44,787,713) | (25,956,924) | (22,171,829) | (24,138,629) | - | - | - |
| % Net Margin | - | - | (2257.1%) | - | - | - | - | - |
Talon Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.